Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech Inc. (NYSE: AIM) announced that its drug candidate, Ampligen®, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022. Oncology experts from Roswell Park Comprehensive Cancer Center will share findings from two ongoing clinical studies involving Ampligen®. The first study evaluates a chemokine-modulatory regimen in colorectal cancer patients, while the second focuses on enhancing cytotoxic T-lymphocyte influx in metastatic triple-negative breast cancer. Both presentations are scheduled for April 11, 2022, in New Orleans, Louisiana.
AIM ImmunoTech announced promising data regarding Ampligen® (rintatolimod) as a treatment for advanced pancreatic cancer in an Early Access Program at Erasmus Medical Center. The treatment showed a median overall survival of 19 months versus historical controls of 7.5 and 12.5 months. A Phase 2 study is set to begin in 2022, aiming to evaluate Ampligen's efficacy post-FOLFIRINOX. The study's positive endpoints include improved survival rates and increased B-cell counts, providing hope for patients with limited treatment options.
AIM ImmunoTech Inc. has announced the sale of its New Brunswick, New Jersey facility for $3.9 million. This strategic move aims to reduce operational expenses by over $1 million annually, allowing the company to focus on advancing its oncology and long-COVID clinical programs. CEO Thomas Equels emphasized the importance of this transaction in streamlining their processes toward FDA and EMA drug approvals. AIM will retain access to the facility for specific activities and plans to lease additional space for product development.
AIM ImmunoTech Inc. has appointed Robert Dickey IV as its new Chief Financial Officer, effective April 4, 2022. Dickey, a financial leader with over 25 years of experience in life sciences and medical devices, replaces Ellen Lintal, who will transition to a consulting role. AIM is poised for significant growth with six ongoing oncology clinical trials and multiple data readouts expected within the next year. The company believes Dickey's extensive background in capital markets and business development will bolster its strategic initiatives.
AIM ImmunoTech has announced participation in a webinar on January 27, 2022, from 2:00 PM to 3:00 PM ET, focusing on the clinical plans for the investigational drug Ampligen in treating myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID.
The session will feature key executives discussing the drug's development, which has shown promise in improving cognitive function among patients. Attendees can register for the event through the provided link.
AIM ImmunoTech announced positive results from a Phase 1/2 clinical study on its intraperitoneal chemo-immunotherapy for advanced recurrent ovarian cancer. The study, demonstrating a well-tolerated safety profile, involved 12 patients and highlighted a 55.6% overall response rate and a median overall survival of 30 months. The promising results support the advancement to a Phase 2 trial, evaluating the immunologic and clinical efficacy of a tumor-loaded αDC1 vaccine combined with cisplatin and chemokine modulation. This development is expected to provide hope for patients and create shareholder value.
AIM ImmunoTech Inc. (NYSE: American AIM) announced a live video webcast presentation on January 26, 2022, at 10:00 AM ET during the Virtual Investor 2022 Top Picks Conference. CEO Thomas K. Equels will present the company’s advancements in therapeutics for cancer, immune disorders, and viral diseases, including COVID-19. The event will feature a corporate presentation followed by an interactive Q&A session. Interested parties may submit questions live or in advance. The presentation will be accessible via the company's website, with a replay available for one year.
AIM ImmunoTech announced that safety data for its drug Ampligen was presented at the Eighth European Scientific Working Group on Influenza conference held virtually from December 4-7, 2021. The Centre for Human Drug Research shared interim results from a Phase 1 clinical study, which involved 40 healthy subjects. The study showed no severe adverse events at various dosages of Ampligen. AIM expects to receive the complete study report in January 2022. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.
AIM ImmunoTech Inc. (NYSE American: AIM) announces CEO Thomas Equels' participation in two significant investor conferences. He will join the 'COVID-19: What’s Next in Prevention, Treatment & Diagnostics' panel at the BioFlorida Conference on December 9, 2021, at 1:45 PM EST, and also partake in the CEO Forum later that day. Additionally, Equels is scheduled to speak at the Benzinga All Access event on December 16, 2021, at 11:20 AM EST. These engagements highlight AIM's commitment to addressing urgent health issues, including COVID-19 and cancer treatments.
AIM ImmunoTech Inc. (NYSE American: AIM) reported its third quarter financial results for 2021, revealing a cash position of $53.7 million as of September 30. R&D expenses rose to $2.0 million, while G&A expenses decreased to $1.8 million, with a net loss of $3.8 million. The company is advancing multiple clinical trials for Ampligen, including a planned Phase 2 study for late-stage pancreatic cancer following positive survival data. AIM is also focused on developing treatments for COVID-19-related cognitive issues and has filed two provisional patents regarding Ampligen therapies.